Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1282479 | 1.00 | MEN1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| Fumaric Acid SCHEMBL29878340 | 1.00 | MEN1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| Fumaric Acid SCHEMBL1282478 | 1.00 | MEN1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| SCHEMBL29878663 | 0.94 | OPRK1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| SCHEMBL30456108 | 0.94 | OPRK1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| SCHEMBL29878034 | 0.94 | OPRK1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| SCHEMBL4545382 | 0.94 | OPRK1 (1.00) | MEN1LMNAMAPK1BLMKMT2A | |
| Fumaric Acid SCHEMBL10418416 | 0.92 | OPRK1 (0.90) | MEN1LMNAMAPK1BLMKMT2A | |
| Fumaric Acid SCHEMBL10418415 | 0.92 | OPRK1 (0.90) | MEN1LMNAMAPK1BLMKMT2A | |
| Maleic Acid SCHEMBL10417819 | 0.91 | MEN1 (0.84) | MEN1LMNAMAPK1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6191126-B1 | TOPICAL ADMINISTERING | ALCON LABORATORIES, INC. | 2001-02-20 | — | — | US | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-06-06 | — | — | US | disclosed |
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | UNIV LOUISIANA STATE (US) | 2023-06-15 | — | — | US | disclosed |
| US-6468971-B1 | Maintaining kidney function during surgery or trauma | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2002-10-22 | — | — | US | disclosed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | disclosed |
| US-5859043-A | Method for maintaining kidney function during surgery or severe trauma under general anesthesia | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1997033580-A1 | MAINTAINING KIDNEY FUNCTION DURING SURGERY OR TRAUMA | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | OPRK1, OPRL1, AVPR1A | MEN1 3533/4885KMT2A 430/4885LMNA 1896/4885 |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | OPRK1, OPRL1, OPRM1 | MEN1 4770/4885KMT2A 1137/4885LMNA 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.